PlasmaGen BioSciences

PlasmaGen BioSciences is an Indian biopharmaceutical company specializing exclusively in plasma protein and specialty care therapeutics. The company manufactures and distributes life-saving plasma-derived medicines for critical care, neurology, hematology, and immunology segments across India and emerging markets.

Core Products and Services

• Intravenous Immunoglobulin (IVIG) – Immunoglobulin products for treating immune deficiencies and autoimmune disorders across neurology and immunology segments

• Human Albumin – Plasma protein used in critical care for hypovolemia, burn management, and organ transplant support

• Coagulation Factors (Factor VIII) – Blood clotting factors for treating hemophilia and coagulation disorders in hematology and critical care

• Hyperimmune Immunoglobulins – Specialized products including Anti-D (intramuscular and intravenous), Anti-Rabies, and Hepatitis B Immunoglobulin for specific therapeutic needs

• Haemocomplettan P – Exclusive distributor of human fibrinogen concentrate for managing massive bleeding in cardiac and liver transplant surgeries

• Cold-Chain Distribution Network – Temperature-controlled distribution infrastructure ensuring product integrity for 5,000+ hospitals and physicians across 70+ cities

Business Model & Revenue Streams

• Manufacturing-driven model using state-of-the-art plasma fractionation facility in Kolar, Karnataka with capacity to process 200,000 liters of plasma annually with expansion potential

• Revenue generation through direct sales to hospitals, physicians, and state governments with no collateral dependencies; operates across critical care, neurology, hematology, oncology, and specialty segments

• Dual revenue streams: manufacturing and selling proprietary plasma products (Albumin, IVIG, Coagulation Factors) and exclusive distribution partnerships (Haemocomplettan P by CSL Behring)

• FY23 revenue of ₹108.26 crore; company reported strong revenue growth post-commercial production ramp-up from March 2024 onwards

• Raised ₹150 crore in latest funding round at ₹1,500+ crore valuation; total funding to date: ₹600+ crore, deploying capital toward international expansion, product portfolio growth, and manufacturing capacity scaling